CASI Net Debt from 2010 to 2026

CASI Stock

USD 0.94 0.05 5.05%

CASI Pharmaceuticals' Net Debt is increasing with very volatile movements from year to year. Net Debt is estimated to finish at about 8.2 M this year. Net Debt is the total debt of CASI Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1995-12-31

Previous Quarter

12 M

Current Value

14.2 M

Quarterly Volatility

21.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 795.3 K, Selling General Administrative of 28.5 M or Other Operating Expenses of 82.3 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0092 or PTB Ratio of 28.32. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with CASI Stock

Check out the analysis of CASI Pharmaceuticals Correlation against competitors.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

The Net Debt trend for CASI Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether CASI Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest CASI Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of CASI Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. CASI Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CASI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Net Debt

Timeline

CASI Net Debt Regression Statistics

	Arithmetic Mean	(20,247,240)
	Coefficient Of Variation	(133.70)
	Mean Deviation	22,823,000
	Median	(9,279,904)
	Standard Deviation	27,070,691
	Sample Variance	732.8T
	Range	91.4M
	R-Value	0.01
	Mean Square Error	781.6T
	R-Squared	0.000097
	Significance	0.97
	Slope	52,727
	Total Sum of Squares	11725.2T

CASI Net Debt History

	2026	8.2 M
	2025	7.8 M
	2024	8.7 M
	2023	4.2 M
	2022	-45.8 M
	2021	-34.4 M
	2020	-53.9 M

Other Fundumenentals of CASI Pharmaceuticals

Net Debt To E B I T D A

CASI Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Net Receivables	Short Term Debt	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.87	-0.65	-0.61	0.78	0.34	0.94	0.64	0.33	0.03	0.81	-0.1	0.47	0.72	0.62	0.86	0.79	0.44	0.36	0.68	0.44	0.0	0.38
Total Stockholder Equity	0.87		-0.91	-0.26	0.48	-0.14	0.83	0.83	-0.15	-0.32	0.47	-0.34	0.0	0.51	0.35	0.69	0.41	0.11	-0.09	0.92	0.77	0.38	0.56
Net Debt	-0.65	-0.91		0.07	-0.22	0.4	-0.69	-0.75	0.38	0.46	-0.21	0.43	0.28	-0.33	-0.03	-0.49	-0.16	0.04	0.35	-0.86	-0.85	-0.46	-0.49
Retained Earnings	-0.61	-0.26	0.07		-0.66	-0.73	-0.64	-0.06	-0.64	-0.46	-0.74	0.03	-0.67	-0.43	-0.46	-0.62	-0.78	-0.62	-0.69	0.0	0.17	0.52	0.18
Accounts Payable	0.78	0.48	-0.22	-0.66		0.56	0.68	0.35	0.5	0.15	0.77	-0.01	0.61	0.69	0.69	0.7	0.77	0.48	0.56	0.25	0.04	-0.24	0.13
Total Liab	0.34	-0.14	0.4	-0.73	0.56		0.35	-0.31	0.94	0.78	0.76	0.51	0.93	0.49	0.51	0.47	0.76	0.77	0.92	-0.37	-0.59	-0.78	-0.43
Total Current Assets	0.94	0.83	-0.69	-0.64	0.68	0.35		0.49	0.32	0.07	0.81	-0.09	0.44	0.74	0.51	0.91	0.77	0.5	0.36	0.61	0.46	-0.17	0.13
Common Stock	0.64	0.83	-0.75	-0.06	0.35	-0.31	0.49		-0.37	-0.36	0.15	-0.38	-0.24	0.28	0.21	0.33	0.14	-0.03	-0.34	0.83	0.63	0.74	0.84
Net Receivables	0.33	-0.15	0.38	-0.64	0.5	0.94	0.32	-0.37		0.79	0.75	0.57	0.97	0.5	0.42	0.48	0.74	0.72	0.96	-0.4	-0.59	-0.79	-0.41
Short Term Debt	0.03	-0.32	0.46	-0.46	0.15	0.78	0.07	-0.36	0.79		0.51	0.69	0.66	0.29	-0.04	0.28	0.46	0.74	0.68	-0.52	-0.78	-0.65	-0.5
Long Term Debt	0.81	0.47	-0.21	-0.74	0.77	0.76	0.81	0.15	0.75	0.51		0.3	0.79	0.72	0.56	0.89	0.91	0.73	0.73	0.24	-0.03	-0.51	-0.13
Treasury Stock	-0.1	-0.34	0.43	0.03	-0.01	0.51	-0.09	-0.38	0.57	0.69	0.3		0.47	0.25	-0.06	0.14	0.3	0.68	0.45	-0.44	-0.58	-0.45	-0.4
Property Plant Equipment	0.47	0.0	0.28	-0.67	0.61	0.93	0.44	-0.24	0.97	0.66	0.79	0.47		0.59	0.62	0.54	0.81	0.69	0.97	-0.25	-0.44	-0.72	-0.26
Current Deferred Revenue	0.72	0.51	-0.33	-0.43	0.69	0.49	0.74	0.28	0.5	0.29	0.72	0.25	0.59		0.51	0.79	0.79	0.63	0.51	0.24	0.06	-0.31	0.0
Short Term Investments	0.62	0.35	-0.03	-0.46	0.69	0.51	0.51	0.21	0.42	-0.04	0.56	-0.06	0.62	0.51		0.45	0.64	0.22	0.51	0.27	0.16	-0.17	0.24
Net Tangible Assets	0.86	0.69	-0.49	-0.62	0.7	0.47	0.91	0.33	0.48	0.28	0.89	0.14	0.54	0.79	0.45		0.85	0.6	0.48	0.47	0.23	-0.32	-0.05
Capital Surpluse	0.79	0.41	-0.16	-0.78	0.77	0.76	0.77	0.14	0.74	0.46	0.91	0.3	0.81	0.79	0.64	0.85		0.75	0.74	0.16	-0.07	-0.5	-0.08
Long Term Debt Total	0.44	0.11	0.04	-0.62	0.48	0.77	0.5	-0.03	0.72	0.74	0.73	0.68	0.69	0.63	0.22	0.6	0.75		0.67	-0.15	-0.39	-0.56	-0.32
Short Long Term Debt	0.36	-0.09	0.35	-0.69	0.56	0.92	0.36	-0.34	0.96	0.68	0.73	0.45	0.97	0.51	0.51	0.48	0.74	0.67		-0.33	-0.52	-0.77	-0.35
Net Invested Capital	0.68	0.92	-0.86	0.0	0.25	-0.37	0.61	0.83	-0.4	-0.52	0.24	-0.44	-0.25	0.24	0.27	0.47	0.16	-0.15	-0.33		0.89	0.59	0.67
Net Working Capital	0.44	0.77	-0.85	0.17	0.04	-0.59	0.46	0.63	-0.59	-0.78	-0.03	-0.58	-0.44	0.06	0.16	0.23	-0.07	-0.39	-0.52	0.89		0.57	0.54
Capital Stock	0.0	0.38	-0.46	0.52	-0.24	-0.78	-0.17	0.74	-0.79	-0.65	-0.51	-0.45	-0.72	-0.31	-0.17	-0.32	-0.5	-0.56	-0.77	0.59	0.57		0.85
Long Term Investments	0.38	0.56	-0.49	0.18	0.13	-0.43	0.13	0.84	-0.41	-0.5	-0.13	-0.4	-0.26	0.0	0.24	-0.05	-0.08	-0.32	-0.35	0.67	0.54	0.85

Click cells to compare fundamentals

About CASI Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as CASI Pharmaceuticals' Net Debt, to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.

	Last Reported	Projected for Next Year
Net Debt	7.8 M	8.2 M
Net Debt To EBITDA	(0.29)	(0.27)

Currently Active Assets on Macroaxis

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill
CSAN	Cosan SA ADR
RKT	Rocket Companies

When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:

How To Invest In CASI

Details

Is CASI Stock a good investment?

Details

What is CASI Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of CASI Pharmaceuticals Correlation against competitors.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

1.622

Quarterly Revenue Growth

(0.60)

Return On Assets

(0.62)

Return On Equity

(10.95)

Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.

It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

CASI Net Debt from 2010 to 2026

Latest CASI Pharmaceuticals' Net Debt Growth Pattern

CASI Net Debt Regression Statistics

CASI Net Debt History

Other Fundumenentals of CASI Pharmaceuticals

CASI Pharmaceuticals Net Debt component correlations

About CASI Pharmaceuticals Financial Statements

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY